← Back to all signals
RESEARCH PAPER ANALYSIS

Icariside II inhibits Epithelial-Mesenchymal transition in metastatic osteosarcoma by antagonizing the miR-194/215 cluster via PGK1.

AI interpretation is pending for this paper.

Open original publication →
PMID40023448
JournalBiochemical pharmacology
Publication Date2025-02-27
Ingested2026-08-02 12:03 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

Osteosarcoma, the most prevalent malignant bone tumor in adolescents, is characterized by its aggressiveness and tendency to metastasize. Despite the advancements in treatment that have improved survival rates for localized cases, metastatic osteosarcoma remains challenging to treat due to the limited efficacy of current therapies and the severe side effects of chemotherapy. Epithelial-mesenchymal transition (EMT) is a key factor in osteosarcoma metastasis, and the miR-194/215 cluster, which is upregulated in osteosarcoma, promotes this process. This study sought to investigate natural compounds that could counteract the miR-194/215 cluster's effects and inhibit osteosarcoma metastasis. By analyzing miRNA databases and clinical data, a signature gene set for the miR-194/215 cluster was established, and the LINCS database was screened to find natural compounds with antagonistic effects. Icariside II, an active component of Epimedium, was identified as a potential inhibitor and was shown to reduce the migration and invasion of osteosarcoma cells in vitro and lung metastasis in vivo. The study utilized various techniques, including Gene Set Enrichment Analysis (GSEA), Drug Affinity Responsive Target Stability (DARTS), Cellular Thermal Shift Assay (CETSA), molecular docking, and enzyme activity assays, to identify phosphoglycerate kinase 1 (PGK1) as the target protein of Icariside II. It was found that Icariside II competitively inhibits PGK1 by binding to its ADP binding pocket, reducing its activity and thus antagonizing the miR-194/215 cluster's promotion of EMT in metastatic osteosarcoma. The results suggest that Icariside II could be a promising therapeutic agent for metastatic osteosarcoma, providing new targets and strategies for clinical treatment.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Pott's Puffy Tumor Mimicking Langerhans Cell Histiocytosis in a Child. Pediatrics international : official journal of the Japan Pediatric Society 28.5 2 A Population-Based Study of Pediatric and Adult Brainstem Glioma: Prognostic Nomograms for Overall and Cancer-Specific Survival. Turkish neurosurgery 62.02 3 Surgical Management of Third Ventricular Colloid Cysts: The Fate of Open Microsurgery. Turkish neurosurgery 63.5 4 Prenatal Ultrasound and MRI Findings in Two Fetuses With Perineal Lipoma. Congenital anomalies 56.0 5 Undiagnosed Undescended Testis in Young Adults in Saudi Arabia: Examination-Based Prevalence, Sociocultural Barriers to Early Care and Public Health Implications. Arab journal of urology 64.5 6 Neuro-ophthalmological disturbances in pediatric posterior fossa tumors: Prevalence, risk factors, and outcomes. Neuro-oncology advances 63.82 7 The oncology and fertility outcomes in patients with ovarian steroid cell tumors: a single center experience. Journal of ovarian research 57.5 8 Predicting brain tumour enhancement from non-contrast MRI with artificial intelligence: a multicohort, retrospective, diagnostic accuracy study. The Lancet medical imaging & theranostics 59.01 9 Correction: Clinical characteristics and risk factors of acute cutaneous graft-vs.-host disease following allogeneic hematopoietic stem cell transplantation in pediatric acute myeloid leukemia: a singlecenter retrospective study. Frontiers in pediatrics 55.0 10 Targeting IL-23p19 in Inflammatory Bowel Disease: The Road Ahead. Journal of inflammation research 57.65 11 When Three Diseases Collide: Human Immunodeficiency Virus, Hodgkin Lymphoma, and Tuberculosis in a Young Child. Pediatric pulmonology 28.5 12 Late recovery from chronic arginine vasopressin deficiency: a multicenter retrospective case-control study. Journal of the Endocrine Society 58.51 13 Early neuroendocrine signatures of polyendocrine metabolic ovarian syndrome risk: Pubertal programming, social brain signals, and novel therapeutic targets. Journal of neuroendocrinology 62.24 14 Obesity in survivors of childhood cancer. Annals of pediatric endocrinology & metabolism 55.06 15 Risk factors for recurrence in pediatric craniopharyngioma: impact of extensive tumor involvement and growth hormone therapy in a multicenter cohort. Annals of pediatric endocrinology & metabolism 63.36 16 Radiological assessment of radon concentration in drinking water from Lagos State University campus, Nigeria. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 58.7 17 Claudin-3 as a marker of intestinal permeability and its relation to inflammatory status in adolescents with functional gastrointestinal disorders. Pediatric research 63.9 18 Reconstructing the cancer journey: The impact of adolescent and young adult (AYA) patient advisory boards on survivor experiences and advocacy. Journal of psychosocial oncology 57.0 19 Safe electrophysiology-guided resection of an epileptogenic non-exophytic hamartoma at the floor of the fourth ventricle in a child. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 56.4 20 Desire for future children and interest in consultation with a fertility specialist among adolescent and young adult (AYA) cancer patients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 57.35 21 Trends in Clinicopathologic Characteristics of Pediatric Differentiated Thyroid Carcinoma: A Single-Center Experience from 1995 to 2022. Endocrinology and metabolism (Seoul, Korea) 56.56 22 Modeling Wilms Tumor Development with Multiple Lineage Human Fetal Kidney Organoids Reveals the Cellular Origin and Specific Drivers of Tumorigenesis. Cancer research 48.5 23 Late effects after novel therapies for childhood cancer: Anticipating the future landscape of health outcomes for survivors. Journal of the National Cancer Institute 65.24 24 Atrophic Papulosis: A Systematic Review of Pediatric Cases. Pediatric dermatology 53.55 25 Menin inhibition in pediatric UBTF-TD myelodysplastic syndrome: molecular rationale and clinical observation. Molecular and cellular pediatrics 63.6 26 Abatacept in biologic-refractory juvenile idiopathic arthritis-associated uveitis: a case-based review. Clinical rheumatology 67.44 27 Paediatric biobanking in the era of precision medicine: ethical, regulatory, and scientific challenges from childhood to adulthood. European journal of pediatrics 53.78 28 Spinal ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes with a focus on the pediatric population (Part III of ependymomas across compartments). Journal of neuro-oncology 63.57 29 Pediatric and Adult Sinonasal Phosphaturic Mesenchymal Tumors: CDKN2A Copy Number Alterations and Their Association with Recurrence. Head and neck pathology 57.5 30 Systematic review of the impact of germline mutations from unrelated bone marrow donors on post-allogeneic transplantation. Expert review of molecular diagnostics 64.09 31 Efficacy and safety of MEK inhibitors for NF1-associated symptomatic, inoperable plexiform neurofibromas: A systematic review and meta-analysis. PloS one 80.82 32 Eosinophilic angiocentric fibrosis in paediatric IgG4-related disease. BMJ case reports 55.2
PATIENT-FRIENDLY SUMMARY

Icariside II inhibits Epithelial-Mesenchymal transition in metastatic osteosarcoma by antagonizing the miR-194/215 cluster via PGK1.

For education only—not personal medical advice.

Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic